Welcome to Paid Research Studies




  • Condition:   Cluster Headache
    Interventions:   Drug: Botulinum toxin type A;   Drug: placebo
    Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   University College, London;   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta;   Catholic University of Valencia;   University Hospital, Essen
    Not yet recruiting

  • Conditions:   Adenovirus;   Anesthesia;   Anxiety;   Anxiolysis;   Autism;   Autistic Disorder;   Bacterial Meningitis;   Bacterial Septicemia;   Benzodiazepine;   Bipolar Disorder;   Bone and Joint Infections;   Central Nervous System Infections;   Convulsions;   Cytomegalovirus Retinitis;   Early-onset Schizophrenia Spectrum Disorders;   Epilepsy;   General Anesthesia;   Gynecologic Infections;   Herpes Simplex Virus;   Infantile Hemangioma;   Infection;   Inflammation;   Inflammatory Conditions;   Intra-abdominal Infections;   Lower Respiratory Tract Infections;   Migraines;   Pain;   Pneumonia;   Schizophrenia;   Sedation;   Seizures;   Skeletal Muscle Spasms;   Skin and Skin-structure Infections;   Treatment-resistant Schizophrenia;   Urinary Tract Infections;   Withdrawal;   Sepsis;   Gram-negative Infection;   Bradycardia;   Cardiac Arrest;   Cardiac Arrhythmia;   Staphylococcal Infections;   Nosocomial Pneumonia;   Neuromuscular Blockade;   Methicillin Resistant Staphylococcus Aureus;   Endocarditis;   Neutropenia;   Headache;   Fibrinolytic Bleeding;   Pulmonary Arterial Hypertension;   CMV Retinitis;   Hypertension;   Chronic Kidney Diseases;   Hyperaldosteronism;   Hypokalemia;   Heart Failure;   Hemophilia;   Heavy Menstrual Bleeding;   Insomnia
    Intervention:   Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    Sponsors:   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The Emmes Company, LLC
    Recruiting

  • Condition:   Migraine
    Interventions:   Drug: Lasmiditan;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Not yet recruiting

  • Condition:   Migraine
    Interventions:   Drug: Erenumab Dose 1;   Drug: Erenumab Dose 2;   Drug: Erenumab Dose 3;   Other: Placebo
    Sponsor:   Amgen
    Not yet recruiting

  • Condition:   Episodic Migraine
    Interventions:   Drug: Erenumab;   Drug: Oral Prophylactic
    Sponsors:   Amgen;   Novartis
    Recruiting